clinical trial · NCT07129759
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma·phase3·not yet recruiting·n = 150
Growth Hormone Deficiency (GHD)LUM-201
brief summary
This is a Multi-national Trial. The Goal of the Trial is to Offer Subjects Who Complete 12 Months in the LUM-201-10 Phase 3 Trial up to an Additional 36 Months of Treatment of LUM-201 While Evaluating Safety and Tolerability of LUM-201.
started
Sep 1, 2026
primary completion
Feb 1, 2030
completion
Feb 1, 2030
last updated
Aug 19, 2025
official title
A Long-term Extension Study to Evaluate the Safety and Tolerability of Daily Oral LUM-201 in Children With Growth Hormone Deficiency (GHD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol